NWBO Northwest Biotherapeutics
- 0.465800
- +0.005800+1.26%
Northwest Biotherapeutics News
Northwest Biotherapeutics Appoints Pat Sarma as Class II Director
Northwest Biotherapeutics Board Veteran Jasinowski Retires
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
Northwest Biotherapeutics (OTCQB: NWBO) announced today that the key development work for the Flaskworks manufacturing system has been completed and an external vendor has been engaged to produce GMP-grade units of the system. In addition, the patent coverage of the Flaskworks system has been expanded: the foundational patent has been issued in the U.S. (and elsewhere) and an additional new patent application has been filed. The Company believes that this broad patent coverage will help it build a strong franchise.
Northwest Biotherapeutics Submits Marketing Authorization Application to UK MHRA for DCvax
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For Glioblastoma
Northwest Biotherapeutics (OTCQB: NWBO) announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax-L for glioblastoma brain cancer.
Northwest Biotherapeutics(NWBO.US) Director Sells US$469.43K in Common Stocks
$Northwest Biotherapeutics(NWBO.US)$ Director MALIK NAVID sold 570K shares of Common Stocks on Nov 16, 17, 2023 at an average price of $0.824 for a total value of $469.43K.Source: Announcement What is
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Northwest Biotherapeutics (OTCQB: NWBO) provided an update today about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company's DCVax-L treatment for glioblastoma.
NW Bio Dips on Announcing Delay in Submission of Marketing Application for DCVax
Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
Northwest Biotherapeutics (OTCQB: NWBO) provided an update today about its progress toward submission of a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company's DCVax-L treatment for glioblastoma.
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
Northwest Biotherapeutics (OTCQB: NWBO) announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB).
Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announces that it plans to submit a Marketing Authorization Application (MAA) in the U.K., to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA), for commercial approval of the Company's DCVax-L treatment for glioblastoma.
Head-To-Head Comparison: Northwest Biotherapeutics (NWBO) and The Competition
Northwest Biotherapeutics (OTCMKTS:NWBO – Get Rating) is one of 993 public companies in the "Pharmaceutical preparations" industry, but how does it compare to its competitors? We will compare Northwes
Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Cross Below 200-Day Moving Average of $0.74
Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Rating)'s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.74 and trad
Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Crosses Below Two Hundred Day Moving Average of $0.75
Shares of Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Rating) passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.75 and traded as
Northwest Biotherapeutics, Advent Get License for Cell Therapy Facility in UK
Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility
One of the First UK Licenses for Commercial Manufacturing of Cell Therapy Products; Allows Global Delivery of the Products BETHESDA, Md., March 20, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) ("NW
Northwest Bio in $11M Loan Agreement With Streeterville Capital
Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200-Day Moving Average of $0.75
Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Rating)'s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.75 and trad
Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Cross Below Two Hundred Day Moving Average of $0.75
Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Rating)'s stock price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average o
Northwest Biotherapeutics (OTCMKTS:NWBO) Share Price Passes Above Fifty Day Moving Average of $0.81
Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Rating) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.81 and traded as high
Analysis
Price Target
No Data
